ScripIn the more than six years since the US Food and Drug Administration approved Novartis AG ’s Kymriah (tisagenlecleucel) and Kite Pharma’s – now part of Gilead Sciences, Inc. – Yescarta (axicabtagen
ScripIt is unclear what kinds of strategic alternatives Bellicum Phamaceuticals, Inc. is considering now that the company has decided to discontinue its two chimeric antigen receptor T-cell (CAR-T) thera
ScripFormer Novartis AG CEO Joe Jimenez and former Novartis Institutes for BioMedical Research Inc. (NIBR) founding president Mark Fishman have brought their drug development expertise to the start-up
ScripReturns from newly public biotechnology companies are far below gains from US biotech stocks in general, but that's not stopping drug developers from filing for initial public offerings, including fiv